Abstract

T helper (Th) cells orchestrate allergic lung inflammation in asthma pathogenesis. Th9 is a novel Th cell subset that mainly produces IL-9, a potent proinflammatory cytokine in asthma. A 7-amino acid peptide (7P) of the hypervariable region 1 (HVR1) of hepatitis C virus has been identified as an important regulator in the type 2 cytokine (IL-4, IL-5, and IL-13) immune response. However, it is unknown whether 7P regulates Th9 cell differentiation during ovalbumin- (OVA-) induced allergic lung inflammation. To address this, we studied wild-type mice treated with 7P and a control peptide in an in vivo mouse model of OVA-induced allergic inflammation and an in vitro cell model of Th9 differentiation, using flow cytometry, cytokine assays, and quantitative PCR. The binding of 7P to CD81 on naïve CD4+ T cells during lung Th9 differentiation was determined using CD81 overexpression and siRNA knockdown analyses. Administration of 7P significantly reduced Th9 cell differentiation after OVA sensitization and exposure. 7P also inhibited Th9 cell differentiation from naïve and memory CD4+ T cells in vitro. Furthermore, 7P inhibited the differentiation of human Th9 cells with high CD81 expression from naïve CD4+ T cells by blocking CD81 signaling. CD81 siRNA significantly reduced Th9 cell differentiation from naïve CD4+ T cells in vitro. Interestingly, CD81 overexpression in human naïve CD4+ T cells also enhanced Th9 development in vitro. These data indicate that 7P may be a good candidate for reducing IL-9 production in asthma.

Highlights

  • Asthma is a chronic airway disease characterized by inflammation, airway hyperreactivity (AHR), and reversible airway obstruction [1]

  • Recent progress towards characterization of the proinflammatory IL-9, IL-5, and IL-13 cytokine families of Th9 cells has added a layer of complexity to our understanding of regulating allergic lung inflammation

  • Levels of IL-9, IL-5, and IL-13 protein in Bronchoalveolar Lavage Fluid (BALF) were significantly decreased in 7-amino acid peptide (7P)-treated mice (Supplementary Figure 1B)

Read more

Summary

Introduction

Asthma is a chronic airway disease characterized by inflammation, airway hyperreactivity (AHR), and reversible airway obstruction [1]. Allergen-specific T helper (Th) 2 cells produce key cytokines (IL-4, IL-5, IL-9, and IL-13) for this process [2]. Th9 cells were first identified as a Th2 subpopulation that produced exceptionally large quantities of cytokine IL-9. IL-9 elicits eosinophilic and lymphocyte inflammation, mucus production, AHR, and subepithelial collagen deposition in the lungs of mice. The use of neutralizing IL-9 antibodies has been shown to reduce inflammation and AHR. Studies using IL-9-deficient mice demonstrated the redundant role of this cytokine in a similar model of Journal of Immunology Research asthma [5]. Mapping studies in mice and humans have shown that IL-9 is an asthma-related gene [6], and antiIL-9 antibodies have been trialed to treat asthma patients in a clinical setting [7]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call